(Q38424862)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882470%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

review article

1 reference

title

Ofatumumab for the treatment of chronic lymphocytic leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882470%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

0 references

1 reference

1

Sebastian Grosicki

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882470%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

3 September 2017

publication date

16 April 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882470%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Hematology

5 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882470%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882470%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882470%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

265-272

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882470%20AND%20SRC:MED&resulttype=core&format=json

Chronic lymphocytic leukaemia: a short overview

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736

Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736

Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736

Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736

Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736

Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736

Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736

Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736

miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736

Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736

Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2015.1037736